Navigation Links
A potential route for human tumor gene therapy
Date:5/20/2008

The type 1 Na+/H+ exchanger (NHE1) is a transmembrane protein found in all eukaryotic cells. One of its functions is to evacuate excessive H+ in the cytoplasm by means of Na+-H+ exchange, resulting in stable intracellular pH value. Inhibition of the upregulation of NHE-1 gene expression in human gastric carcinoma cells can induce intracellular acidification, resulting in apoptosis of tumor cells, which is helpful for the treatment of tumors.

This study, performed by a team led by Professor Hai-Feng Liu, is described in a research article to be published on April 14, 2008 in the World Journal of Gastroenterology.

Previous studies have proven that the significantly higher expression level of NHE1 protein in gastric carcinoma tissues than in normal gastric tissues is closely associated with the genesis and progression of tumors, suggesting that NHE1 can be used as the target in treatment of tumors. However, further studies are needed to know whether the intervention of the antisense NHE1 gene can decrease type 1 Na+/H+ exchange of membranous ion exchange protein in gastric carcinoma cells, and the effects on the biological behaviors of gastric carcinoma cells.

The purpose of transfection of the antisense NHE1 gene into the human gastric carcinoma cell line SGC-7901 is to investigate the effects of antisense therapy targeting the NHE1 gene on the malignant phenotypes of gastric carcinoma cells. The results indicate NHE1 genes are among the important genes in maintaining the phenotypes of the SGC-7901 cell line. NHE1 might be closely associated with the malignant biological behaviors of tumor cells, so the phenotypes of the tumor will be restrained when NHE1 is inhibited.

This is an interesting article examining the effect of inhibiting NHE1 on tumor survival. It would be useful to make clearer in the abstract what NHE1 is. Further research should be done on gene therapy for gastric carcinomas.


'/>"/>

Contact: Jing Zhu
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. High Growth Potential for Carotid Stent and Thoracic Aortic Stent Graft Markets
2. Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome
3. Estimated 3.2 million Burmese potentially affected by cyclone
4. Most Baby Boomers are Financially Unprepared for a Potential Disability
5. New report: Arthritis is a potential barrier to physical activity for adults with diabetes
6. Improving anxiety treatment through the help of brain imaging: A potential future treatment strategy
7. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
8. Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted
9. Potential viral therapy weapon for difficult cancers is safe and effective in study
10. Penn researchers find potential in yeast for selecting Lou Gehrigs disease drugs
11. Minnesota partnership advances potential MS therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash Association, ... enlisted New York City-based sports and entertainment marketing firm Leverage Agency as its ... for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, naming ...
(Date:3/29/2017)... ... ... pollen is the main cause of hay fever in the United States, with an estimated ... from May to July each year; with the worst time for sufferers being June and ... ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in independent ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Youth Futures ... great success and feedback from high school and college students who have participated in ... held July 7-23 and YFI is now accepting applications for enrollment. Visit ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sports Brand ... brace, which retails normally at $29.97; for the remaining days of March, the ... also been reduced to a special price of just $10 (regular retail price $19.97). ...
(Date:3/29/2017)... Louisiana (PRWEB) , ... March 29, 2017 , ... ... in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of ... Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over the counter ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017  Glenmark Pharmaceuticals, a global pharmaceutical company, ... investigational fixed-dose combination of mometasone furoate (25 mcg) ... a nasal spray being studied for the treatment ... a recently completed Phase 3 trial assessing the ... versus mometasone, olopatadine or placebo. "We ...
(Date:3/29/2017)...  Maxor National Pharmacy Services, LLC ("Maxor"), a leading ... Leah Bailey as General Counsel.  Bailey will serve ... With more than 13 years of experience ... on health care, Bailey joins the Maxor team coming ... advised the PBM, Specialty, and Mail Order business areas ...
(Date:3/29/2017)... , March 29, 2017 Varian Medical Systems ... report results for the second quarter of fiscal year 2017 ... 2017.  The news release will be followed by a teleconference ... news release and a link to the conference call webcast ... .  To access the teleconference call and replay: ...
Breaking Medicine Technology: